ISMP Alerts

Hazardous Packaging Error

URGENT – HAZARDOUS SITUATION – PLEASE REACT IMMEDIATELY  

ISMP is aware of an extremely hazardous packaging error involving certain cisatracurium products from Meitheal Pharmaceuticals. While the outer carton identifies the vials inside as cisatracurium, the vials contained in the carton are labeled phenylephrine injection. A photograph appears below. The vials actually contain cisatracurium and have caps appropriate for a paralyzing agent. However, this cap warning may not be noticed, since the vial is labeled phenylephrine.
 
Due to the nature of this situation and the potential for death if the these vials are used as phenylephrine injection in patients who are not intubated and ventilated, we urge facilities to immediately examine any and all cartons of cisatracurium from Meitheal Pharmaceuticals for this serious packaging error. The possibility that any of these vials were actually distributed should also be considered. ISMP has confirmed that both the FDA and the manufacturer are aware of this situation and that a recall is imminent. 

cisatracurium
Carton labeled properly as cisatracurium, but the vials within are mislabeled as phenylephrine but actually contain cisatracurium.

 

More Alerts

B. Braun recently announced a new presentation of potassium chloride for injection concentrate (2 mEq/mL) in a 250 mL EXCEL container plastic bag with blue and red labeling, and a blocked medication port. The 250 mL product is a pharmacy bulk package and should only be used in a pharmacy admixture
On December 22, 2021, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for PAXLOVID, consisting of oral tablets of nirmatrelvir that are co-packaged with oral tablets of ritonavir (an FDA-approved antiretroviral agent). Indications Emergency use of Paxlovid is
Ever since the US Food and Drug Administration (FDA) authorized the emergency use of a specific formulation (10 mcg/0.2 mL) of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine for children ages 5 through 11 years, reports of mix-ups with the Pfizer-BioNTech COVID-19 vaccine